| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192785 | Journal of Thoracic Oncology | 2015 | 9 Pages |
Abstract
Despite preselecting patients for targeted treatment, BASALT-1 did not meet its primary objective during Stage 1. PI3K pathway activation can be detected using ctDNA, but may not be the main oncogenic driver in NSCLC. Combinations of PI3K inhibitors with other agents may demonstrate greater efficacy than monotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Johan F. MD, PhD, Jean-Luc MD, Filippo MD, Francesco MD, Tommaso MD, Jhanelle E. MD, Wu-Chou MD, Enriqueta MD, PhD, Hiroshige MD, Cesare MD, Grace K. MD, Sumitra MD, Martin MD, PhD, Paola MD, Gena Atalla MS, CPM, Pantelia PhD, Ying A. PhD,